General Clinical Chemistry Analyzers and Accessories
Abcam LY2940680 (Taladegib), 5MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Qstatin, 25MG
MW 293.2 Da, Purity >=98%. A potent, and selective Vibrio QS inhibitor which affects Vibrio harveyi LuxR homologues, the well-conserved master transcriptional regulators for QS in Vibrio species. QStatin binds tightly to a putative ligand-binding pocket in SmcR, the LuxR homologue in V. vulnificus, and changes the flexibility of the protein, thereby altering its transcription regulatory activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT1720 hydrochloride, 25MG
MW 506 Da, Purity >=98%. Selective SIRT1 activator (EC₅₀ = 0.16 μM), 230-fold less potent for SIRT2 and SIRT3. Induce autophagy.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RITA, p53 activator, 5MG
MW 292.4 Da, Purity >98%. p53 activator. Tricyclic thiophene derivative that binds to p53 and induces its accumulation in tumor cells. Prevents p53-HDM2 (MDM2) interaction in vitro and in vivo and affects p53 interaction with several negative regulators. Induces expression of p53 target genes and apoptosis in various tumor cell lines expressing wild-type p53.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Monochlorobimane, 5MG
MW 226.66 Da, Purity >=98%. Monochlorobimane is a cell-permeant probe for quantifying glutathione levels in cells. It is essentially nonfluorescent until it reacts with a thiol group. It readily reacts with several low molecular weight thiols, including cysteine, glutathione, N-acetylcysteine, mercaptopurine, peptides and plasma thiols. The glutathione conjugate of monochlorobimane has an excitation/emission maxima ~394/490 nm.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 25MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW 6471, PPAR alpha antagonist, 1MG
MW 619.7 Da, Purity >98%. Potent PPAR alpha antagonist (IC₅₀ = 240 nM). Drives displacement of co-activators from PPAR alpha. Promotes recruitment of co-repressor proteins SMRT and NCoR to ligand binding domain. Inhibits cardiomyocyte differentiation in mouse embryonic stem cells. Causes reduced expression of cardiac sarcomeric proteins and specific genes in a time-dependent manner.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 10MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 10MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
YSI 3P LifeScience L-Lactate Membrane Kit (4 each)
For in-vitro diagnostic use with YSI enzyme-based lactate analyzers (YSI 1500, 2300, 2700, 2900 series and 7100 analyzers) labeled for clinical use. Also for non-diagnostic use. Reactive ingredients: immobilized L-Lactate oxidase. Store membranes refrigerated; do not freeze. Return plastic holder with unused membranes to foil pouch. Discard when expiration date is past. Stability of enzyme preparation is variable. See appropriate YSI instruction manual for membrane activity tests. US patent 3979274. NOTE: Requires 2-day shipping during summer months.
Abcam Qstatin, 5MG
MW 293.2 Da, Purity >=98%. A potent, and selective Vibrio QS inhibitor which affects Vibrio harveyi LuxR homologues, the well-conserved master transcriptional regulators for QS in Vibrio species. QStatin binds tightly to a putative ligand-binding pocket in SmcR, the LuxR homologue in V. vulnificus, and changes the flexibility of the protein, thereby altering its transcription regulatory activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 5MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW 6471, PPAR alpha antagonist, 5MG
MW 619.7 Da, Purity >98%. Potent PPAR alpha antagonist (IC₅₀ = 240 nM). Drives displacement of co-activators from PPAR alpha. Promotes recruitment of co-repressor proteins SMRT and NCoR to ligand binding domain. Inhibits cardiomyocyte differentiation in mouse embryonic stem cells. Causes reduced expression of cardiac sarcomeric proteins and specific genes in a time-dependent manner.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sitravatinib, 25MG
MW 629.7 Da, Purity =98%. Broad spectrum receptor tyrosine kinase inhibitor (e.g. Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3). Better efficacy in mouse models than imatinib and crizotinib.
The product is subject to the following: Abcam Restricted Use Statement